Shanghai Junshi Biosciences (SZSC:1877) - Prezzo delle azioni, notizie e analisi

La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

1877 Panoramica delle azioni

Shanghai Junshi Biosciences Co., Ltd., società biofarmaceutica, è impegnata nella scoperta, nello sviluppo e nella commercializzazione di vari farmaci nelle aree terapeutiche dell'oncologia, del metabolismo, delle malattie autoimmuni, neurologiche, del sistema nervoso e infettive nella Repubblica Popolare Cinese.

Informazioni sull'azienda

1877 analisi fondamentale
Punteggio fiocco di neve
Valutazione	2/6
Crescita futura	2/6
Prestazioni passate	0/6
Salute finanziaria	5/6
Dividendi	0/6

Premi

Si prevede che i ricavi cresceranno 23.24% all'anno

Analisi del rischio

Attualmente non redditizio e non si prevede che diventerà redditizio nei prossimi 3 anni

Shanghai Junshi Biosciences Co., Ltd. Concorrenti

Sichuan Kelun-Biotech Biopharmaceutical

SEHK:6990

HK$43.0b

InnoCare Pharma

SEHK:9969

HK$14.4b

3SBio

SEHK:1530

HK$15.2b

CanSino Biologics

SEHK:6185

HK$10.1b

Storia dei prezzi e prestazioni

Riepilogo dei massimi storici, delle variazioni e dei cali di prezzo di tutti i tempi per Shanghai Junshi Biosciences
Prezzi storici delle azioni
Prezzo attuale dell'azione	HK$14.46
Massimo di 52 settimane	HK$24.60
Minimo di 52 settimane	HK$9.17
Beta	0.35
1Variazione di 1 mese	38.24%
Variazione a 3 mesi	14.04%
Variazione di 1 anno	-19.40%
3Variazione a 3 anni	-65.32%
Variazione a 5 anni	n/a
Variazione dall'IPO	-83.63%

Notizie e aggiornamenti recenti

Recent updates

Rendimenti per gli azionisti

	1877	HK Biotechs	HK Mercato
7D	-5.5%	-0.4%	-1.0%
1Y	-19.4%	2.7%	20.3%

Ritorno vs Industria: 1877 ha avuto una performance inferiore rispetto al Hong Kong Biotechs che ha registrato un rendimento 16.7 % nell'ultimo anno.

Rendimento vs Mercato: 1877 ha avuto una performance inferiore al mercato Hong Kong che ha registrato un rendimento 6.2 % nell'ultimo anno.

Volatilità dei prezzi

Is 1877's price volatile compared to industry and market?
1877 volatility
1877 Average Weekly Movement	12.0%
Biotechs Industry Average Movement	10.5%
Market Average Movement	8.9%
10% most volatile stocks in HK Market	18.9%
10% least volatile stocks in HK Market	4.3%

Prezzo delle azioni stabile: 1877 non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi.

Volatilità nel tempo: La volatilità settimanale ( 7% ) di 1877 è rimasta stabile nell'ultimo anno.

Informazioni sull'azienda

Fondato	I dipendenti	AMMINISTRATORE DELEGATO	Sito web
2012	2,532	Cong Li	www.junshipharma.com

Shanghai Junshi Biosciences Co., Ltd. Riepilogo dei fondamenti

Come si confrontano gli utili e i ricavi di Shanghai Junshi Biosciences con la sua capitalizzazione di mercato?
1877 statistiche fondamentali
Capitalizzazione di mercato	HK$29.42b
Guadagni(TTM)	-HK$2.11b
Ricavi(TTM)	HK$1.77b

8.0x

Rapporto P/S

-6.7x

Rapporto P/E

1877 è sopravvalutato?

Vedi Fair Value e analisi di valutazione

Guadagni e ricavi

Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM)
1877 Conto economico (TTM)
Ricavi	CN¥1.62b
Costo del fatturato	CN¥565.18m
Profitto lordo	CN¥1.05b
Altre spese	CN¥2.98b
Guadagni	-CN¥1.93b

Ultimi guadagni dichiarati

Jun 30, 2024

Prossima data di guadagno

Oct 29, 2024

Utile per azione (EPS)	-1.96
Margine lordo	65.09%
Margine di profitto netto	-119.28%
Rapporto debito/patrimonio netto	38.5%

Come si è comportato 1877 nel lungo periodo?

Vedi performance storica e confronto

1877 Panoramica delle azioni

Premi

Analisi del rischio

Shanghai Junshi Biosciences Co., Ltd. Concorrenti

SEHK:6990

HK$43.0b

SEHK:9969

HK$14.4b

SEHK:1530

HK$15.2b

SEHK:6185

HK$10.1b

Storia dei prezzi e prestazioni

Notizie e aggiornamenti recenti

Shanghai Junshi Biosciences Co., Ltd. Announces the Approval of New Drug Application for Ongericimab Injection

Shanghai Junshi Biosciences Co., Ltd. to Report Q3, 2024 Results on Oct 30, 2024

Shanghai Junshi Biosciences Co., Ltd. Receives Notice of Approval for Clinical Trial

Shanghai Junshi Biosciences Co., Ltd. Receives Approval by the European Commission for Marketing of Toripalimab

Second quarter 2024 earnings released: CN¥0.36 loss per share (vs CN¥0.46 loss in 2Q 2023)

Shanghai Junshi Biosciences Co., Ltd. Announces Acceptance of Supplemental New Drug Application for Toripalimab as First-Line Treatment of Unresectable/Metastatic Melanoma

Recent updates

Shanghai Junshi Biosciences Co., Ltd. Announces the Approval of New Drug Application for Ongericimab Injection

Shanghai Junshi Biosciences Co., Ltd. to Report Q3, 2024 Results on Oct 30, 2024

Shanghai Junshi Biosciences Co., Ltd. Receives Notice of Approval for Clinical Trial

Shanghai Junshi Biosciences Co., Ltd. Receives Approval by the European Commission for Marketing of Toripalimab

Second quarter 2024 earnings released: CN¥0.36 loss per share (vs CN¥0.46 loss in 2Q 2023)

Shanghai Junshi Biosciences Co., Ltd. Announces Acceptance of Supplemental New Drug Application for Toripalimab as First-Line Treatment of Unresectable/Metastatic Melanoma

Shanghai Junshi Biosciences Co., Ltd. Receives the Acceptance Notice for the Investigational New Drug Application for WJ47156 Tablets

Shanghai Junshi Biosciences Co., Ltd. to Report First Half, 2024 Results on Aug 31, 2024

Shanghai Junshi Biosciences Co., Ltd. Receives the Drug Registration Certificate Issued by the National Medical Products Administration

Shanghai Junshi Biosciences Co., Ltd. Announces Board Changes

Shanghai Junshi Biosciences Co., Ltd Announces Approval of the sNDA for Toripalimab for the 1st-Line Treatment of Small Cell Lung Cancer

Shanghai Junshi Biosciences Co., Ltd. Receives Drug Registration Certificate Issued by the National Medical Products Administration

Shanghai Junshi Biosciences Co., Ltd. Announces Phase III Clinical Study of Toripalimab in Combination with Bevacizumab for the First-Line Treatment of Advanced Hepatocellular Carcinoma

Shanghai Junshi Biosciences Co., Ltd., Annual General Meeting, Jun 21, 2024

First quarter 2024 earnings released

Shanghai Junshi Biosciences Co., Ltd. Receives Notice from the Drug Office, Department of Health, the Government of the Hong Kong Special Administration Region

No longer forecast to breakeven

Shanghai Junshi Biosciences Co., Ltd. Announces Approval of the sNDA for Toripalimab for the 1st-Line Treatment of Renal Cancer

Shanghai Junshi Biosciences Co., Ltd. Announces the Acceptance of the Supplemental New Drug Applications for Ongericimab Injection

Shanghai Junshi Biosciences Co., Ltd. to Report Q1, 2024 Results on Apr 30, 2024

Full year 2023 earnings released: CN¥2.32 loss per share (vs CN¥2.60 loss in FY 2022)

Full year 2023 earnings released: CN¥2.28 loss per share (vs CN¥2.60 loss in FY 2022)

Shanghai Junshi Biosciences Co., Ltd. Provides Earnings Guidance for the Year Ended December 31, 2023

Shanghai Junshi Biosciences Co., Ltd. Announces Change of Chief Executive Officer

Shanghai Junshi Biosciences Co., Ltd. and Topalliance Biosciences Inc Appoints Li Ning as Vice Chairman of the Third Session of the Board

Shanghai Junshi Biosciences Co., Ltd. Announces Publication of Results from Toripalimab, a Randomized Phase 3 Trial of Toripalimab for the Treatment of Metastatic or Recurrent Triple-negative Breast Cancer in Nature Medicine

Shanghai Junshi Biosciences Co., Ltd. Announces New Indications of TUOYI and MINDEWEI Included in New Edition of National Reimbursement Drug List

Shanghai Junshi Biosciences Announces New Chemical Entity Application for Toripalimab Accepted by Australia's TGA

Coherus and Junshi Biosciences Announces Publication of Positive Final Overall Survival Results of Jupiter-02, A Phase 3 Trial Evaluating Loqtorzi (Toripalimab-Tpzi) as Treatment for Nasopharyngeal Carcinoma, in the Journal of the American Medical Association

New minor risk - Profitability

Third quarter 2023 earnings released: CN¥0.42 loss per share (vs CN¥0.75 loss in 3Q 2022)

Coherus Biosciences, Inc. and Shanghai Junshi Biosciences Co., Ltd. Biosciences Announce FDA Approval of Loqtorzi (Toripalimab-Tpzi) in All Lines of Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma

Shanghai Junshi Biosciences Co., Ltd. Directors Appointments

Shanghai Junshi Biosciences Co., Ltd. Announces Phase III Clinical Study of Toripalimab for the First-Line Treatment of Melanoma Met Primary Endpoint

Shanghai Junshi Biosciences Co., Ltd. (SEHK:1877) announces an Equity Buyback for CNY 60 million worth of its shares.

Shanghai Junshi Biosciences Co., Ltd. Announces JS207 Injection Received the Notice of Approval for Clinical Trial

Shanghai Junshi Biosciences Co., Ltd. Announces Resignation of Wu Hai as Non-Executive Director

Second quarter 2023 earnings released: CN¥0.46 loss per share (vs CN¥0.56 loss in 2Q 2022)

Shanghai Junshi Biosciences Co., Ltd. (SEHK:1877) announces an Equity Buyback for CNY 60 million worth of its shares.

Shanghai Junshi Biosciences Co., Ltd. Announces Acceptance of the Supplemental New Drug Application for Toripalimab as the First-Linetreatment of Advanced RCC

Shanghai Junshi Biosciences Co., Ltd. Announces Board Changes

Shanghai Junshi Biosciences Co., Ltd. Announces JS207 Injection Received the Acceptance Notice For the Investigational New Drug Application

Shanghai Junshi Biosciences Co., Ltd., Annual General Meeting, Jun 30, 2023

Shanghai Junshi Biosciences Co., Ltd. Announces Acceptance of Supplemental New Drug Application for Toripalimab in Combination with Chemotherapy for Treatment of Advanced Triple - Negative Breast Cancer

Shanghai Junshi Biosciences Co., Ltd. Announces Phase III Clinical Study of Toripalimab in Combination with Chemotherapy for the First-Line Treatment of ES-SCLC Met Primary Endpoint

First quarter 2023 earnings released: CN¥0.55 loss per share (vs CN¥0.44 loss in 1Q 2022)

Now 21% undervalued after recent price drop

Shanghai Junshi Biosciences Co., Ltd and Coherus Biosciences, Inc. Announce Positive Results of A Final Analysis of Overall Survival from the Pivotal Study JUPITER-02

Shanghai Junshi Biosciences Co., Ltd. Announces JS401 Injection Receival the Acceptance Notice for The Investigational New Drug Application

Shanghai Junshi Biosciences Co., Ltd. Provides Earnings Guidance for the Year Ended December 31, 2022

Shanghai Junshi Biosciences Co., Ltd. Announces Acceptance of NDA for VV116 in China

Now 26% undervalued

Shanghai Junshi Biosciences Co., Ltd, Shanghai Juntop Biosciences Co., Ltd. and Vigonvita Life Sciences Co., Ltd. Announce Progress of the Clinical Studies of VV116

Shanghai Junshi Biosciences Co., Ltd. Receives Acceptance Notice for the Investigational New Drug Application

Shanghai Junshi Biosciences Co., Ltd Announces Nejm Publication of Results of Phase 3 Study of Vv116 Versus Paxlovid for Adults At High Risk for Progression to Severe Covid-19

Junshi Biosciences and Coherus Share Update on the FDA Review of the Biologics License Application for Toripalimab as Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma

Shanghai Junshi Biosciences Co., Ltd. Announces Updated Clinical data from Phase I study of anti-BTLA antibody Tifcemalimab in Treatment of Relapsed/Refractory Lymphomas at 64th ASH Annual Meeting

Shanghai Junshi Biosciences Co., Ltd. Announces Board Changes

Shanghai Junshi Biosciences Co., Ltd. Announces Acceptance of Marketing Authorization Application of Toripalimab